Industry

Covid-19 Harnessing the power of digital technologies and data sharing

Covid-19: Harnessing the power of digital technologies and data sharing

Digital technologies and data-driven science offer solutions to control and mitigate the effects of Covid-19 on health and the economy. What is at stake for Europe?

EU-ToxRisk EU project

EU Project : EU-ToxRisk

EU-ToxRisk is an Integrated European ‘Flagship’ Programme Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st century. The vision of this project is to drive the required paradigm shift in toxicological testing away from ‘black box’ animal testing towards a toxicological assessment based on human cell responses and a comprehensive mechanistic understanding of cause-consequence ...

Alternative approaches to animal testing

Alternative approaches to animal testing

In 1959, The Principles of Humane Experimental Technique was published by Russell and Burch, introducing the 3Rs concept (replacement, reduction, and refinement) regarding animal use in the scientific community. Just over 60 years later, it is timely to review progress to date and the future outlook regarding alternative approaches to animal testing.

A Scientist's Opinion : interview with Prof. Maurice Whelan about Animal testing

A scientist’s opinion : Interview with Professor Maurice Whelan about animal testing

Animal testing, a scientist’s opinion Interview with Maurice Whelan, head of EURL ECVAM (European Union Reference Laboratory for alternatives to animal testing (EURL ECVAM) at the JRC (Joint Research Centre of the European Comission) in Ispra, Italy. How do you think progress is going on reducing animal use for scientific purposes, and what is the ...

A Scientist's Opinion : interview with Pierfranco Conte about Animal testing

A scientist’s opinion : Interview with Professor PierFranco Conte about animal testing

Animal testing, a scientist’s opinion Interview with Professor PierFranco Conte, Full Professor of Oncology at the University of Padova and Director of the Division of Medical Oncology 2 at the Istituto Oncologico Veneto in Padova. In your opinion, why is animal use for scientific purposes still so common place? Are animal models still essential for ...

A Scientist's Opinion : interview with Dr Jason Johnson about Animal testing

A scientist’s opinion : Interview with Dr Jason Johnson about animal testing

Animal testing, a scientist’s opinion Interview with Dr Jason Johnson, British Heart Foundation Senior Research Fellow, Associate Professor of Cardiovascular Pathology, and leads the Laboratory of Cardiovascular Pathology at Bristol Medical School, University of Bristol. As a scientist, in general do you find that the 3Rs concept is something that is routinely thought of when ...

A scientist’s opinion : Interview with Aroon Hingorani about re-engineering pharmaceutical research

A scientist’s opinion : Interview with Aroon Hingorani about re-engineering pharmaceutical research

Re-engineering pharmaceutical research, a scientist’s opinion Interview with Aroon Hingorani, Professor of Genetic Epidemiology at University College London. Could you speculate what you think are the biggest causes of drug failure? It is well recognised that the number one cause for drug failure is a lack of efficacy of the drug in the intended indication, ...

A scientist’s opinion : Interview with Dr Denis Lacombe about re-engineering pharmaceutical research

A scientist’s opinion : Interview with Dr Denis Lacombe about re-engineering pharmaceutical research

Re-engineering pharmaceutical research, a scientist’s opinion Interview with Dr Denis Lacombe, Director General of the European Organisation for Research and Treatment of Cancer (EORTC). Can you tell me a bit about the European Organisation for Research and Treatment of Cancer (EORTC)? We are a non-governmental, not-for-profit organisation established for 60 years, focusing on survival and ...

Re-engineering pharmaceutical research for better patient outcomes

Re-engineering pharmaceutical research for better patient outcomes

A so-called ‘productivity crisis’ has been ascribed to the pharmaceutical research and development industry. Despite increases in investment and funding, this has not corresponded to increases in the approval of novel drugs. Why do so many drugs fail to receive approval, and what other means should we be focusing on for the benefit of patients?

A scientist’s opinion : Interview with Dr Síle Lane about re-engineering pharmaceutical research

A scientist’s opinion : Interview with Dr Síle Lane about re-engineering pharmaceutical research

Re-engineering pharmaceutical research, a scientist’s opinion Interview with Dr Síle Lane, head of international campaigns and policy at Sense About Science. Undisclosed clinical trial results are unfortunately common - how does this impact progression in research and treatment? When results from clinical trials aren’t published it means the same research can get repeated unnecessarily. This ...

scroll to top